# Recordati to acquire worldwide rights to Signifor and Osilodrostat from Novartis

Recordati signed an agreement with Novartis to acquire worldwide rights to Signifor and Osilodrostat for $390 million, with Novartis supplying products during a transitional period.

- Type: Acquisition
- Announced: 2019-07-12
- Value: $390.0M
- Status: announced
- Products: Signifor, Signifor LAR, Osilodrostat

## Companies

- [Novartis](https://endata.com/companies/32041.md) (target)
- [Recordati](https://endata.com/companies/40611.md) (acquirer)

## Sources

- [reuters.com](https://www.reuters.com/article/markets/europe/recordati-to-acquire-worldwide-rights-to-signifor-and-osilodrostat-lci699-idUSASB01SZK/), 2019-07-12: "Upon completion of transaction a consideration of $390 million will be due to Novartis."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.